NOVARTIS

ALPELISIB

PIVIKTO®

200 mg Film-Coated Tablet (200 mg daily dose)
1 x 200mg + 1 x 50mg Film-Coated Tablets (250 mg daily dose)
2 x 150 mg Film-Coated Tablets (300 mg daily dose)

Antineoplastic Agent [Phosphatidylinositol-3-kinase (Pi3K) Inhibitor]

DESCRIPTION AND COMPOSITION

Pharmaceutical form

Film-coated tablets

- 50 mg: Light pink, unscored, round and curved with beveled edges, imprinted with "L7" on one side and "NVR" on the other side.
- 150 mg: Pale red, unscored, ovaloid and curved with beveled edges, imprinted with "UL7" on one side and "NVR" on the other side.
- 200 mg: Light red, unscored, ovaloid and curved with beveled edges, imprinted with "YL7" on one side and "NVR" on the other side.

Certain dosage strengths and dosage forms may not be available in all countries.

Active substance

Film-coated tablets containing alpelisib

Excipients

Film-coated tablet core: Microcrystalline cellulose, mannitol, sodium starch glycolate, hypromellose and magnesium stearate.

Coating material: Hypromellose, titanium dioxide, macrogol / polyethylene glycol (PEG), talc, iron oxide red, and iron oxide black.

Information might differ in some countries.

INDICATIONS

Alpelisib (Pivikto®) is an alpha-specific class I phosphatidylinositol-3-kinase (PIK3CA) inhibitor indicated for the treatment of postmenopausal women, and men, with hormone receptor positive, HER2-negative, advanced breast cancer with a PIK3CA mutation in combination with fulvestrant after disease progression following an **endocrine-based regimen**.

DOSAGE REGIMEN AND ADMINISTRATION

Treatment with alpelisib (Pivikto®) should be initiated by a physician experienced in the use of anticancer therapies.

Dosage regimen

General target population

Patients with HR (hormone receptor) positive, HER2 negative advanced breast cancer should be selected for treatment with alpelisib (Pivikto®), based on the presence of a PIK3CA mutation in tumor or plasma specimens, using a validated test. If a mutation is not detected in a plasma specimen, test tumor tissue if available.

There was no treatment benefit demonstrated in patients without PIK3CA mutations in the phase III clinical study (see section CLINICAL STUDIES).

The recommended dose of alpelisib (Pivikto®) is 300 mg (2×150 mg film-coated tablets) taken orally, once daily on a continuous basis. Alpelisib (Pivikto®) should be taken immediately following food, at approximately the same time each day (see section CLINICAL PHARMACOLOGY and section INTERACTIONS). The maximum recommended daily dose of alpelisib (Pivikto®) is 300 mg. If a dose of alpelisib (Pivikto®) is missed, it can be taken immediately following food and within 9 hours after the time it is usually administered. After more than 9 hours, the dose should be skipped for that day. On the next day, alpelisib (Pivikto®) should be taken at its usual time. If the patient vomits after taking the alpelisib (Pivikto®) dose, the patient should not take an additional dose on that day and should resume the usual dosing schedule the next day, at the usual time.

When co-administered with alpelisib (Pivikto®), the recommended dose of fulvestrant is 500 mg administered intramuscularly on days 1, 15 and, 29, and once monthly thereafter. Please refer to the full prescribing information of fulvestrant.

Treatment should continue as long as clinical benefit is observed or until unacceptable toxicity occurs. Dosing modifications may be necessary to improve tolerability.

Dosing modifications

The recommended daily dose of alpelisib (Pivikto®) is 300 mg. Management of severe or intolerable adverse drug reactions (ADRs) may require temporary dosing interruption, reduction, and/or discontinuation of alpelisib (Pivikto®). If dosing reduction is required, the dosing reduction guidelines for ADRs are listed in Table 1. A maximum of 2 dosing reductions are recommended, after which the patient should be discontinued from treatment with alpelisib (Pivikto®). Dosing reduction should be based on worst preceding toxicity.

Table 1   Recommended dosing reduction guidelines for adverse drug reactions for alpelisib (Pivikto®)[1]

Alpelisib (Pivikto®) dose level	Dose and schedule	Number and strength of tablets
Starting dose	300 mg/day continuously	2 x 150 mg tablets
First dose reduction	250 mg/day continuously	1 x 200 mg tablet and 1 x 50 mg tablet
Second dose reduction	200 mg/day continuously	1 x 200 mg tablet
[1]Only one dose reduction is permitted for pancreatitis.		

Tables 2, 3, 4 and 5 summarize recommendations for dosing interruption, reduction or discontinuation of alpelisib (Pivikto®) in the management of specific ADRs. Clinical judgment of the treating physician, including confirmation of laboratory values if deemed necessary, should guide the management plan of each patient based on the individual benefit/risk assessment for treatment with alpelisib (Pivikto®).

Hyperglycemia

Consultation with a Healthcare Professional (HCP) with experience in the management of hyperglycemia should be considered and lifestyle changes as per local guidelines (e.g. American Diabetes Association (ADA)), including exercise and dietary advice should be recommended/reinforced (e.g. small frequent meals, low carbohydrate, high fiber, low processed food intake, three macronutrient balanced meals and 2 optional small snacks rather than one large meal).

In patients with risk factors for hyperglycemia, monitor fasting glucose more closely and as clinically indicated (see section WARNINGS AND PRECAUTIONS).

Table 2   Dosing modification and management for hyperglycemia[1]

Fasting Glucose (FG)[2]	Recommendation
Dose modifications and management should only be based on fasting glucose (plasma/blood) values.	
>ULN - 160 mg/dL or >ULN - 8.9 mmol/L	No alpelisib (Pivikto®) dose adjustment required. Initiate or intensify oral anti-diabetic treatment[2].
>160 to 250 mg/dL or >8.9 to 13.9 mmol/L.	No alpelisib (Pivikto®) dose adjustment required. Initiate or intensify oral anti-diabetic treatment[2]. If FG does not decrease to ≤160 mg/dL or 8.9 mmol/L within 21 days with appropriate oral anti-diabetic treatment[2,3], reduce alpelisib (Pivikto®) dose by 1 dose level, and follow FG value specific recommendations.
>250 to 500 mg/dL or >13.9 to 27.8 mmol/L	Interrupt alpelisib (Pivikto®). Initiate or intensify oral anti-diabetic treatment[2] and consider additional anti-diabetic medications such as insulin[3] for 1 to 2 days until hyperglycemia resolves, as clinically indicated. Administer intravenous hydration and consider appropriate treatment (e.g. intervention for electrolyte/ketoacidosis/hyperosmolar disturbances). If FG decreases to ≤160 mg/dL or 8.9 mmol/L within 3 to 5 days under appropriate anti-diabetic treatment, resume alpelisib (Pivikto®) at next lower dose level. If FG does not decrease to ≤160 mg/dL or 8.9 mmol/L within 3 to 5 days under appropriate anti-diabetic treatment, consultation with a physician with expertise in the treatment of hyperglycemia is recommended. If FG does not decrease to ≤160 mg/dL or 8.9 mmol/L within 21 days following appropriate anti-diabetic treatment [2,3], permanently discontinue alpelisib (Pivikto®) treatment.
>500 mg/dL or >27.8 mmol/L	Interrupt alpelisib (Pivikto®).

Fasting Glucose (FG)[2]	Recommendation
Dose modifications and management should only be based on fasting glucose (plasma/blood) values.	
	Initiate or intensify appropriate anti-diabetic treatment [2,3] (administer intravenous hydration and consider appropriate treatment (e.g. intervention for electrolyte/ketoacidosis/hyperosmolar disturbances)), re-check within 24 hours and as clinically indicated.
	If FG decreases to (≤ 500 mg/dL) or (≤ 27.8 mmol/L), then follow FG value specific recommendations for (<500 mg/dL).
	If FG is confirmed at > 500 mg/dL or (> 27.8 mmol/L), permanently discontinue alpelisib (Pivikto®) treatment.

[1] *Fasting Glucose levels reflect hyperglycemia grading according to CTCAE Version 4.03. CTCAE=Common Terminology Criteria for Adverse Events.*

[2] *Applicable anti-diabetic medications, like metformin, SGLT2 inhibitors or insulin sensitizers (such as thiazolidinediones or dipeptidyl peptidase-4 inhibitors), should be initiated and respective prescribing information should be reviewed for dosing and dose titration recommendations, including local diabetic treatment guidelines. Metformin was recommended in the phase III clinical study with the following guidance: Metformin 500 mg once daily should be initiated. Based on tolerability, metformin dose may be increased to 500 mg bid, followed by 500 mg with breakfast, and 1,000 mg with dinner, followed by further increase to 1,000 mg bid if needed (see section WARNINGS AND PRECAUTIONS).*

[3] *As recommended in the phase III clinical study, insulin may be used for 1 to 2 days until hyperglycemia resolves. However, this may not be necessary in the majority of alpelisib-induced hyperglycemia, given the short half-life of alpelisib and the expectation of glucose levels normalizing after interruption of alpelisib (Pivikto®)*

Rash

Oral antihistamine administration may be considered prophylactically, at the time of initiation of treatment with alpelisib (Pivikto®). Based on the severity of rash, alpelisib (Pivikto®) may require dose interruption, reduction, or discontinuation as described in Table 3 (see section ADVERSE DRUG REACTIONS).

Table 3   **Dosing modification and management for rash[1]**

Grade	Recommendation
All Grades	Consultation with a dermatologist should always be considered
Grade 1 (<10% body surface area (BSA) with active skin toxicity)	No alpelisib (Pivikto®) dose adjustment required. Initiate topical corticosteroid treatment. Consider adding oral antihistamine treatment to manage symptoms. If active rash is not improved within 28 days of appropriate treatment, add a low dose systemic corticosteroid.
Grade 2 (10 to 30% BSA with active skin toxicity)	No alpelisib (Pivikto®) dose adjustment required. Initiate or intensify topical corticosteroid and oral antihistamine treatment. Consider low dose systemic corticosteroid treatment. If rash improves to Grade ≤1 within 10 days, systemic corticosteroid may be discontinued.

Grade	Recommendation
Grade 3 (e.g: severe rash not responsive to medical management). (>30% BSA with active skin toxicity)	Interrupt alpelisib (Pivikto®) until rash improves to Grade ≤1. Initiate or intensify topical/systemic corticosteroid and antihistamine treatment. Once rash improves to Grade ≤1, resume alpelisib (Pivikto®) at next lower dose level.
Grade 4 (e.g: severe bullous, blistering or exfoliating skin conditions). (any % BSA associated with extensive superinfection, with IV antibiotics indicated; life-threatening consequences)	Permanently discontinue alpelisib (Pivikto®).
[1] Grading according to CTCAE Version 5.0	

Table 4   Dosing modification and management for diarrhea or colitis[1]

Grade[1]	Recommendation
Grade 1	No alpelisib (Pivikto®) dose adjustment required. Initiate appropriate medical therapy and monitor as clinically indicated.
Grade 2	Interrupt alpelisib (Pivikto®) dose until improvement to Grade ≤1, then resume alpelisib (Pivikto®) at same dose level. For recurrent Grade ≥2, interrupt alpelisib (Pivikto®) dose until improvement to Grade ≤1, then resume alpelisib (Pivikto®) at the next lower dose level. Initiate or intensify appropriate medical therapy and monitor as clinically indicated[2].
Grade 3	Interrupt alpelisib (Pivikto®) dose until improvement to Grade ≤1, then resume alpelisib (Pivikto®) at the next lower dose level. Initiate or intensify appropriate medical therapy and monitor as clinically indicated[2,3].
Grade 4	Permanently discontinue alpelisib (Pivikto®)[3].

[1] Grading according to CTCAE Version 5.0.

[2] For Grade 2 and 3 colitis consider additional treatment, such as steroids.

[3] For Grade 3 and 4 diarrhea patients should additionally be managed according to local standard of care, including electrolyte monitoring, administration of antiemetics and antidiarrheal medicinal products and/or fluid replacement and electrolyte supplements, as clinically indicated.

Other toxicities

Table 5   **Dosing modification and management for other toxicities (excluding hyperglycemia, rash and diarrhea)[1]**

Grade	Recommendation
Grade 1 or 2	No alpelisib (Pivikto®) dose adjustment required. Initiate appropriate medical therapy and monitor as clinically indicated[2,3].
Grade 3	Interrupt alpelisib (Pivikto®) dose until improvement to Grade ≤1, then resume alpelisib (Pivikto®) at the next lower dose level[2].
Grade 4	Permanently discontinue alpelisib (Pivikto®).

[1] *Grading according to CTCAE Version 5.0 .*

[2] *For Grade 2 and 3 pancreatitis, interrupt alpelisib (Pivikto®) dose until improvement to Grade ≤1 and resume at next lower dose level. Only one dose reduction is permitted. If toxicity recurs, permanently discontinue alpelisib (Pivikto®) treatment.*

[3]*For Grade 2 total bilirubin elevation, interrupt alpelisib (Pivikto®) dose until improvement to Grade ≤ 1 and resume at the same dose if improved in ≤ 14 days or resume at the next lower dose level if improved in > 14 days.*

Refer to the full prescribing information for fulvestrant for dose modification guidelines in the event of toxicity and other relevant safety information.

Special populations

Renal impairment

Based on population pharmacokinetic analysis, no dose adjustment is necessary in patients with mild or moderate renal impairment (see section CLINICAL PHARMACOLOGY). Caution should be used in patients with severe renal impairment as there is no experience with alpelisib (Pivikto®) in this population (see section CLINICAL PHARMACOLOGY).

Hepatic impairment

Based on a hepatic impairment study in non-cancer subjects with impaired hepatic function, no dose adjustment is necessary in patients with mild, moderate and severe hepatic impairment (Child-Pugh class A, B or C, respectively) (see section CLINICAL PHARMACOLOGY).

Refer to the full prescribing information of fulvestrant for dose modifications related to hepatic impairment.

Pediatric patients (below 18 years)

The safety and efficacy of alpelisib (Pivikto®) in pediatric patients have not been established.

Geriatric patients (65 years or above)

No dosage regimen adjustment is required in patients 65 years or above (see section CLINICAL STUDIES).

Method of administration

Alpelisib (Pivikto®) tablets should be swallowed whole (tablets should not be chewed, crushed or split prior to swallowing). Tablets that are broken, cracked, or otherwise not intact should not be ingested.

CONTRAINDICATIONS

Alpelisib (Pivikto®) is contraindicated in patients with hypersensitivity to the active substance or to any of the excipients.

WARNINGS AND PRECAUTIONS

Hypersensitivity (including anaphylactic reaction)

Serious hypersensitivity reactions (including anaphylactic reaction and anaphylactic shock), manifested by symptoms including, but not limited to, dyspnea, flushing, rash, fever or tachycardia were reported in patients treated with alpelisib (Pivikto®) in clinical studies (see section ADVERSE DRUG REACTIONS). Angioedema has been reported in the post marketing setting in patients treated with Alpelisib (Pivikto®) (see section ADVERSE DRUG REACTIONS). Alpelisib (Pivikto®) should be permanently discontinued and should not be re-introduced in patients with serious hypersensitivity reactions. Appropriate treatment should be promptly initiated.

Severe cutaneous reactions

Severe cutaneous reactions have been reported with alpelisib (Pivikto®). In the Phase III clinical study, Stevens-Johnson syndrome (SJS) and erythema multiforme (EM) were reported in 1 (0.4%) and 3 (1.1%) patients, respectively. Drug reaction with eosinophilia and systemic symptoms (DRESS) has been reported in the post marketing setting (see section ADVERSE DRUG REACTIONS).

Alpelisib (Pivikto®) treatment should not be initiated in patients with history of severe cutaneous reactions.

Patients should be advised of the signs and symptoms of severe cutaneous reactions (e.g. a prodrome of fever, flu-like symptoms, mucosal lesions or progressive skin rash). If signs or symptoms of severe cutaneous reactions are present, alpelisib (Pivikto®) should be interrupted until the etiology of the reaction has been determined. A consultation with a dermatologist is recommended. If a severe cutaneous reaction is confirmed, alpelisib (Pivikto®) should be permanently discontinued. Alpelisib (Pivikto®) should not be reintroduced in patients who have experienced previous severe cutaneous reactions. If a severe cutaneous reaction is not confirmed, alpelisib (Pivikto®) may require treatment interruption, dose reduction, or treatment discontinuation as described in Table 3 Dose modification and management for rash (see section DOSAGE REGIMEN AND ADMINISTRATION).

Hyperglycemia

Severe hyperglycemia, in some cases associated with hyperglycemic hyperosmolar nonketotic syndrome (HHNKS) or ketoacidosis, has been observed in patients treated with alpelisib (Pivikto®). Some cases of ketoacidosis with fatal outcome have been reported in the post marketing setting.

Hyperglycemia was reported in 64.8% of patients treated with alpelisib (Pivikto®) in the phase III clinical study. Grade 2 (FPG 160 to 250 mg/dL), 3 (FPG >250 to 500 mg/dL) or 4 (FPG > 500 mg/dL) hyperglycemia were reported in 15.8%, 33.1% and 3.9% of patients, respectively, in phase III clinical study.

In the phase III clinical study, patients with a history of diabetes mellitus intensified anti-diabetic medication(s) while on treatment with alpelisib (Pivikto®); therefore, these patients require monitoring and possibly intensified anti-diabetic treatment. Patients with poor glycemic control may be at a higher risk of developing severe hyperglycemia and associated complications. Patients with risk factors for hyperglycemia such as obesity (BMI ≥30), elevated FPG or HbA1c at or above the upper limit of normal, or age ≥75 are at a higher risk of developing severe hyperglycemia. Schedule for monitoring fasting glucose is presented in Table 6.

Patients should be advised of the signs and symptoms of hyperglycemia (e.g. excessive thirst, urinating more often than usual or higher amount of urine than usual, increased appetite with weight loss).

Table 6   Schedule of fasting glucose monitoring

	Recommended schedule for the monitoring of fasting glucose and HbA1c levels in all patients treated with alpelisib (Pivikto®)	Recommended schedule of monitoring of fasting glucose and HbA1c levels in patients with diabetes, pre-diabetes, BMI ≥30 or age ≥75 years treated with alpelisib (Pivikto®)
At screening, before initiating treatment with alpelisib (Pivikto®)	Test for fasting plasma glucose (FPG), HbA1c, and optimize the patient's level of blood glucose.	
After initiating treatment with alpelisib (Pivikto®)	Monitor/self-monitor fasting glucose at least once every week for the first 2 weeks, then at least once every 4 weeks, and as clinically indicated, according to the instructions of a healthcare professional*.	Monitor/self-monitor fasting glucose more frequently for the first few weeks of treatment. Then continue to monitor fasting glucose as frequently as needed to manage hyperglycemia according to the instructions of a healthcare professional*.
If hyperglycemia develops after initiating treatment with alpelisib (Pivikto®)	HbA1c should be monitored every 3 months as clinically indicated.	
	Monitor fasting glucose regularly, as per local standard of care and at least until fasting glucose decreases to normal levels.	
	During treatment with antidiabetic medication, continue monitoring fasting glucose at least once a week for 8 weeks, followed by once every 2 weeks, and monitor fasting glucose according to the instructions of a healthcare professional with expertise in the treatment of hyperglycemia.	
All glucose monitoring should be performed at the physician's discretion as clinically indicated.		

In patients with hyperglycemia, 163/187 (87.2%) were managed with anti-diabetic medication and 142/187 (75.9%) reported use of metformin as single agent or in combination with other anti-diabetic medication. The maximum dose of metformin recommended in phase III clinical study was 2,000 mg per day.

In patients with hyperglycemia of at least Grade 2 (FPG 160 to 250 mg/dL), median time to improvement by at least 1 Grade of the first event was 8 days (95% CI of 8 to 10 days). In all patients with elevated FPG, who continued fulvestrant treatment after discontinuing alpelisib (Pivikto®), all FPG levels returned to baseline (normal).

Based on the severity of the hyperglycemia, alpelisib (Pivikto®) may require dose interruption, reduction, or discontinuation as described in Table 2 Dose modification and management for hyperglycemia. (see section DOSAGE REGIMEN AND ADMINISTRATION).

Pneumonitis

Pneumonitis including serious cases of pneumonitis/acute interstitial lung disease have been reported in alpelisib (Pivikto®) treated patients in clinical studies. Patients should be advised to promptly report any new or worsening respiratory symptoms. In patients who have new or worsening respiratory symptoms or are suspected to have developed pneumonitis, alpelisib (Pivikto®) treatment should be interrupted immediately and the patient should be evaluated for pneumonitis. A diagnosis of non-infectious pneumonitis should be considered in patients presenting with non-specific respiratory signs and symptoms such as hypoxia, cough, dyspnea, or interstitial infiltrates on radiologic exams and in whom infectious, neoplastic, and other causes have been excluded by means of appropriate investigations. Alpelisib (Pivikto®) should be permanently discontinued in all patients with confirmed pneumonitis.

Diarrhea or colitis

Severe diarrhea and clinical consequences, such as dehydration and acute kidney injury have been reported during treatment with alpelisib (Pivikto®) in clinical studies(see Table 7 ADVERSE DRUG REACTIONS). In the phase III clinical study, Grade 2 and 3 diarrhea were reported in 18.3% and 6.7% of patients, respectively. There were no reported cases of Grade 4 diarrhea. Among patients with Grade 2 or 3 diarrhea, median time to onset was 46 days (range: 1 to 442 days).

Colitis has been reported in the post marketing setting in patients treated with alpelisib (Pivikto®) (see section ADVERSE DRUG REACTIONS).

In the phase III clinical study, dose reductions of alpelisib (Pivikto®) were required in 6% of patients and 2.8% of patients permanently discontinued alpelisib (Pivikto®) due to diarrhea.

Patients should be monitored for diarrhea and additional symptoms of colitis, such as abdominal pain and mucus or blood in stool. Based on the severity of the diarrhea or colitis, Alpelisib (Pivikto®) may require dose interruption, reduction, or discontinuation as described in Table 4 (SEE SECTION DOSAGE REGIMEN AND ADMINISTRATION).

Patients should be advised to notify their healthcare provider if diarrhea or additional symptoms of colitis occur while taking alpelisib (Pivikto®). Patients should be managed according to local standard of care medical management, including electrolyte monitoring, administration of anti-emetics and antidiarrheal medications and/or fluid replacement and electrolyte supplements, as clinically indicated. In case of colitis, additional treatment, such as steroids, may be considered as clinically indicated.

Osteonecrosis of the jaw

Caution should be exercised when alpelisib (Pivikto®) and bisphosphonates or denosumab are used either simultaneously or sequentially. Alpelisib (Pivikto®) treatment should not be initiated in patients with ongoing osteonecrosis of the jaw from previous or concurrent treatment with

bisphosphonates/denosumab. Patients should be advised to promptly report any new or worsening oral symptoms (such as dental mobility, pain or swelling, non-healing of mouth sores, or discharge) during treatment with alpelisib (Pivikto®).

In patients who develop osteonecrosis of the jaw, standard medical management should be initiated.

Adverse drug reactions

Summary of the safety profile

The overall safety evaluation of alpelisib (Pivikto®) is based on data from the phase III clinical study of 572 patients (571 post-menopausal women and 1 male) who were randomized in a 1:1 ratio to receive alpelisib (Pivikto®) plus fulvestrant or placebo plus fulvestrant; 284 of whom received alpelisib (Pivikto®) at the recommended starting dose of 300 mg dose in combination with fulvestrant, using the proposed treatment regimen.

The median duration of exposure to alpelisib (Pivikto®) plus fulvestrant was 8.2 months with 59.2% patients exposed for >6 months.

Alpelisib (Pivikto®) dose reductions due to adverse events (AEs), regardless of causality occurred in 57.7% of patients receiving alpelisib (Pivikto®) plus fulvestrant and in 4.5% of patients receiving placebo plus fulvestrant. Permanent discontinuations due to AEs were reported in 25% of patients receiving alpelisib (Pivikto®) plus fulvestrant and 4.5% of patients receiving placebo and/or fulvestrant. The most common AEs leading to treatment discontinuation of both alpelisib (Pivikto®) and/or fulvestrant were hyperglycemia (6.3%), rash (3.2%), diarrhea (2.8%), and fatigue (2.1%).

On-treatment deaths, regardless of causality, were reported in 7 patients (2.5%) treated with alpelisib (Pivikto®) plus fulvestrant vs. 12 patients (4.2%) treated with placebo plus fulvestrant. In alpelisib (Pivikto®) plus fulvestrant treated patients, disease progression (5 patients, 1.8%) was the most frequent cause of death; the others were one each for cardio-respiratory arrest and second primary malignancy, neither of which were considered related to treatment with alpelisib (Pivikto®).

The most common ADRs in alpelisib (Pivikto®) plus fulvestrant treated patients (reported at a frequency ≥20% and for which the frequency for alpelisib (Pivikto®) plus fulvestrant exceeds the frequency for placebo plus fulvestrant) were hyperglycemia, diarrhea, rash, nausea, fatigue and asthenia, decreased appetite, stomatitis, vomiting and weight decreased.

The most common Grade 3/4 ADRs (reported at a frequency ≥2% in the alpelisib (Pivikto®) plus fulvestrant arm and for which the frequency for alpelisib (Pivikto®) plus fulvestrant exceeds the frequency for placebo plus fulvestrant) were hyperglycemia, rash and maculo-papular rash, fatigue, diarrhea, lipase increased, hypertension, hypokalemia, anemia, weight decreased, gamma-glutamyltransferase increased, lymphopenia, nausea, stomatitis, alanine aminotransferase increased and mucosal inflammation.

Tabulated summary of adverse drug reactions from clinical studies

ADRs from the phase III clinical study (Table 7) are listed by MedDRA system organ class. Within each system organ class, the ADRs are ranked by frequency, with the most frequent reactions first. Within each frequency grouping, ADRs are presented in order of decreasing

seriousness. In addition, the corresponding frequency category for each ADR is based on the following convention (CIOMS III): very common (≥1/10); common (≥1/100 to <1/10); uncommon (≥1/1,000 to <1/100); rare (≥1/10,000 to <1/1,000); very rare (<1/10,000).

Table 7 **Adverse drug reactions observed in the phase III clinical study**

Adverse drug reactions	Alpelisib (Pivikto®) + Fulvestrant N= 284 n (%) All Grades	Placebo + Fulvestrant N= 287 n (%) All Grades	Alpelisib (Pivikto®) + Fulvestrant N= 284 n (%) Grades 3/4	Placebo + Fulvestrant N=287 n (%) Grades 3/4	Frequency category for alpelisib (Pivikto®) + Fulvestrant All Grades
Blood and lymphatic system disorders					
Anemia	29 (10.2)	15 (5.2)	11 (3.9)	3 (1.0)	Very common
Lymphopenia	14 (4.9)	3 (1.0)	7 (2.5)	3 (1.0)	Common
Thrombocytopenia	6 (2.1)	0	2 (0.7)	0	Common
Eye disorders					
Vision blurred	14 (4.9)	2 (0.7)	1 (0.4)	0	Common
Dry eye	10 (3.5)	1 (0.3)	0	0	Common
Gastrointestinal disorders					
Diarrhea	164 (57.7)	45 (15.7)	19 (6.7)	1 (0.3)	Very common
Nausea	127 (44.7)	64 (22.3)	7 (2.5)	1 (0.3)	Very common
Stomatitis[1]	85 (29.9)	18 (6.3)	7 (2.5)	0	Very common
Vomiting	77 (27.1)	28 (9.8)	2 (0.7)	1 (0.3)	Very common
Abdominal pain	47 (16.5)	32 (11.1)	4 (1.4)	3 (1.0)	Very common
Dyspepsia	32 (11.3)	16 (5.6)	0	0	Very common
Toothache	12 (4.2)	6 (2.1)	1 (0.4)	0	Common
Gingivitis	10 (3.5)	2 (0.7)	1 (0.4)	0	Common
Cheilitis	8 (2.8)	0	0	0	Common
Gingival pain	8 (2.8)	0	0	0	Common
Pancreatitis	1 (0.4)	0	1 (0.4)	0	Uncommon
General disorders and administrative site conditions					
Fatigue[2]	120 (42.3)	83 (28.9)	15 (5.3)	3 (1.0)	Very common
Mucosal inflammation	54 (19.0)	3 (1.0)	6 (2.1)	0	Very common
Peripheral edema	43 (15.1)	15 (5.2)	0	1 (0.3)	Very common
Pyrexia	41 (14.4)	14 (4.9)	2 (0.7)	1 (0.3)	Very common
Mucosal dryness [3]	33 (11.6)	12 (4.2)	1 (0.4)	0	Very common
Edema [4]	17 (6.0)	1 (0.3)	0	0	Common
Immune system disorders					

Adverse drug reactions	Alpelisib (Pivikto®) + Fulvestrant N= 284 n (%) All Grades	Placebo + Fulvestrant N= 287 n (%) All Grades	Alpelisib (Pivikto®) + Fulvestrant N= 284 n (%) Grades 3/4	Placebo + Fulvestrant N=287 n (%) Grades 3/4	Frequency category for alpelisib (Pivikto®) + Fulvestrant All Grades
Hypersensitivity [5]	10 (3.5)	0	2 (0.7)	0	Common
Infections and infestations					
Urinary tract infection[6]	29 (10.2)	15 (5.2)	2 (0.7)	3 (1.0)	Very common
Investigations					
Weight decreased	76 (26.8)	6 (2.1)	11 (3.9)	0	Very common
Blood creatinine increased	29 (10.2)	4 (1.4)	5 (1.8)	0	Very common
Gamma-glutamyltransferase increased	27 (9.5)	20 (7.0)	11 (3.9)	14 (4.9)	Common
Alanine aminotransferase increased	23 (8.1)	16 (5.6)	7 (2.5)	6 (2.1)	Common
Lipase increased	18 (6.3)	11 (3.8)	14 (4.9)	10 (3.5)	Common
Glycosylated hemoglobin increased	9 (3.2)	0	0	0	Common
Metabolism and nutrition disorders					
Hyperglycemia	184 (64.8)	29 (10.1)	105 (37.0)	2 (0.7)	Very common
Decreased appetite	101 (35.6)	30 (10.5)	2 (0.7)	1 (0.3)	Very common
Hypokalemia	28 (9.9)	5 (1.7)	12 (4.2)	1 (0.3)	Common
Hypocalcemia	12 (4.2)	4 (1.4)	3 (1.1)	1 (0.3)	Common
Dehydration	10 (3.5)	4 (1.4)	1 (0.4)	3 (1.0)	Common
Ketoacidosis [7]	2 (0.7)	0	2 (0.7)	0	Uncommon
Musculoskeletal and connective tissue disorders					
Muscle spasms	19 (6.7)	11 (3.8)	0	0	Common
Myalgia	19 (6.7)	8 (2.8)	1 (0.4)	0	Common
Osteonecrosis of jaw	12 (4.2)	4 (1.4)	4 (1.4)	2 (0.7)	Common
Nervous system disorders					
Headache	51 (18.0)	38 (13.2)	2 (0.7)	0	Very common
Dysgeusia [8]	51 (18.0)	10 (3.5)	1 (0.4)	0	Very common
Psychiatric disorders					
Insomnia	21 (7.4)	12 (4.2)	0	0	Common
Renal and Urinary disorders					
Acute kidney injury	15 (5.3)	2 (0.7)	5 (1.8)	1 (0.3)	Common
Respiratory, thoracic and mediastinal disorders					
Pneumonitis [9]	5 (1.8)	1 (0.3)	1 (0.4)	1 (0.3)	Common

Adverse drug reactions	Alpelisib (Pivikto®) + Fulvestrant N= 284 n (%) All Grades	Placebo + Fulvestrant N= 287 n (%) All Grades	Alpelisib (Pivikto®) + Fulvestrant N= 284 n (%) Grades 3/4	Placebo + Fulvestrant N=287 n (%) Grades 3/4	Frequency category for alpelisib (Pivikto®) + Fulvestrant All Grades
Skin and subcutaneous tissue disorders					
Rash [10]	147 (51.8)	21 (7.3)	56 (19.7)	1 (0.3)	Very common
Alopecia	56 (19.7)	7 (2.4)	0	0	Very common
Pruritus	52 (18.3)	17 (5.9)	2 (0.7)	0	Very common
Dry skin [11]	51 (18.0)	11 (3.8)	1 (0.4)	0	Very common
Erythema [12]	17 (6.0)	2 (0.7)	2 (0.7)	0	Common
Dermatitis [13]	10 (3.5)	3 (1.0)	2 (0.7)	0	Common
Palmar-plantar erythrodysesthesia syndrome	5 (1.8)	1 (0.3)	0	0	Common
Erythema multiforme	3 (1.1)	0	2 (0.7)	0	Common
Stevens-Johnson syndrome	1 (0.4)	0	1 (0.4)	0	Uncommon
Vascular disorders					
Hypertension	24 (8.5)	15 (5.2)	13 (4.6)	9 (3.1)	Common
Lymphedema	15 (5.3)	6 (2.1)	0	0	Common

[1] *Stomatitis: also includes aphthous ulcer and mouth ulceration*

[2] *Fatigue: also includes asthenia*

[3] *Mucosal dryness: also includes dry mouth, vulvovaginal dryness*

[4] *Edema: also includes face swelling, face edema, eyelid edema*

[5] *Hypersensitivity: also includes allergic dermatitis*

[6] *Urinary tract infection: also includes single case of urosepsis*

[7] *Ketoacidosis: also includes diabetic ketoacidosis (see section WARNINGS AND PRECAUTIONS)*

[8] *Dysgeusia : also includes ageusia, hypogeusia*

[9] *Pneumonitis: also includes interstitial lung disease*

[10] *Rash: also includes rash maculo-papular, rash macular, rash generalized, rash-papular, rash pruritic*

[11] *Dry skin: also includes skin fissures, xerosis, xeroderma*

[12] *Erythema: also includes erythema generalized*

[13] *Dermatitis: also includes dermatitis acneiform*

Table 8   **Laboratory abnormalities observed in the phase III study**

Laboratory abnormalities	Alpelisib (Pivikto®) + Fulvestrant N= 284 n (%) All Grades	Placebo + Fulvestrant N= 287 n (%) All Grades	Alpelisib (Pivikto®) + Fulvestrant N= 284 n (%) Grades 3/4	Placebo + Fulvestrant N=287 n (%) Grades 3/4	Frequency category for alpelisib (Pivikto®) + Fulvestrant All Grades
Hematological parameters					
Lymphocyte count decreased	147 (51.8)	116 (40.4)	23 (8.1)	13 (4.5)	Very common
Hemoglobin decreased	118 (41.5)	83 (28.9)	12 (4.2)	3 (1.0)	Very common
Activated partial thromboplastin time increased	60 (21.1)	45 (15.7)	2 (0.7)	1 (0.3)	Very common
Platelet count decreased	39 (13.7)	17 (5.9)	3 (1.1)	0	Very common
Biochemical parameters					
Glucose plasma increased	223 (78.5)	99 (34.5)	110 (38.7)	3 (1.0)	Very common
Creatinine increased	190 (66.9)	71 (24.7)	8 (2.8)	2 (0.7)	Very common
Gamma-glutamyl transferase increased	148 (52.1)	127 (44.3)	30 (10.6)	29 (10.1)	Very common
Alanine aminotransferase increased	124 (43.7)	99 (34.5)	10 (3.5)	7 (2.4)	Very common
Lipase increased	119 (41.9)	73 (25.4)	19 (6.7)	17 (5.9)	Very common
Calcium corrected decreased	76 (26.8)	57 (19.9)	6 (2.1)	4 (1.4)	Very common
Glucose plasma decreased	73 (25.7)	40 (13.9)	1 (0.4)	0	Very common
Albumin decreased	39 (13.7)	22 (7.7)	0	0	Very common
Potassium decreased	39 (13.7)	8 (2.8)	16 (5.6)	2 (0.7)	Very common
Magnesium decreased	31 (10.9)	12 (4.2)	1 (0.4)	0	Very common

Adverse drug reactions from spontaneous reports and literature cases (frequency not known)

The following adverse drug reactions have been derived from post-marketing experience with alpelisib (Pivikto®) via spontaneous case reports and literature cases. Because these reactions are reported voluntarily from a population of uncertain size, it is not possible to reliably estimate their frequency which is therefore categorized as not known.

Table 9   **Adverse drug reactions from spontaneous reports and literature (frequency not known)**

Gastrointestinal disorders
Colitis

Metabolism and nutrition disorders
Hyperglycemic hyperosmolar nonketotic syndrome (HHNKS)

| Skin and subcutaneous tissue disorders |
| Angioedema |
| Drug reaction with eosinophilia and systemic symptoms (DRESS) |

Description of selected ADRs and treatment recommendations, where applicable

Hyperglycemia

In the phase III clinical study, hyperglycemia (FPG > 160 mg/dL) was reported in 184 (64.8%) of patients. An event of hyperglycemia resolved to ≤Grade 1 (FPG < 160 mg/dL) in 166 (88.8%) of the 187 patients. Dose interruptions and adjustments due to hyperglycemic events were reported in 26.8% and 28.9% of patients, respectively, in the alpelisib (Pivikto®) plus fulvestrant arm. Hyperglycemic events leading to discontinuation of alpelisib (Pivikto®) and/or fulvestrant were reported in 19 (6.7 %) patients.

Based on baseline FPG and HbA1c values, 56% of patients were considered pre-diabetic (FPG > 100 to 126 mg/dL (5.6 to 6.9 mmol/L) and/or HbA1c 5.7 to 6.4%) and 4.2% of patients were considered diabetic (FPG≥126 mg/dL (≥7.0 mmol/L) and/or HbA1c ≥ 6.5 %). There were no patients with type 1 diabetes mellitus based on reported medical history. Among those pre-diabetic patients at baseline, 74.2% experienced hyperglycemia (any Grade) when treated with alpelisib (Pivikto®). Among the patients who had Grade ≥2 (FPG 160 to 250 mg/dL) hyperglycemia , the median time to first occurrence of Grade ≥2 (FPG > 160 to 250 mg/dL) hyperglycemia was 15 days (range: 5 days to 517 days) (based on laboratory findings). The median duration of Grade 2 (FPG >160 to 250 mg/dL) or higher hyperglycemia (based on laboratory findings) was 10 days (95% CI: 8 to 13 days).

Rash

In the phase III clinical study, rash events (including rash maculo-papular, rash macular, rash generalized, rash papular, rash pruritic, dermatitis and dermatitis acneiform) were reported in 153 (53.9%) patients. Rash may be accompanied by pruritus and dry skin in some cases. Rash was predominantly mild or moderate (Grade 1 or 2) and responsive to therapy. Maximum Grade 2 and 3 rash events were reported in 13.7% and 20.1% of patients, respectively. There were no Grade 4 cases of rash reported. Among the patients with Grade 2 or 3 rash, the median time to first onset of Grade 2 or 3 rash was 12 days (range: 2 days to 220 days). Dose interruptions and dose adjustments due to rash were reported in 21.8% and 9.2% of patients, respectively, in the alpelisib (Pivikto®) plus fulvestrant arm.

Topical corticosteroid treatment should be initiated at the first signs of rash and oral corticosteroids should be considered for moderate to severe rashes. Additionally, antihistamines are recommended to manage symptoms of rash. In the Phase III study, among the patients who developed a rash, 73.9% (113/153) reported use of at least one topical corticosteroid and 67.3% (103/153) of at least one oral antihistamine. Systemic corticosteroid were administered for rash events in 23% (66/284) of patients. Of the patients who received systemic corticosteroids, 55% (36/66) received oral corticosteroids for rash. At least one event of rash resolved in the majority of the patients, 141 out of 153 patients (92%). Discontinuation of alpelisib (Pivikto®) and/or fulvestrant treatment due to rash events occurred in 12 patients (4.2%).

A subgroup of 86 patients received anti rash treatment, including anti-histamines, prior to onset of rash. In these patients, rash was reported less frequently than in the overall population, for all Grades rash (26.7% vs 53.9%), Grade 3 rash (11.6% vs 20.1%) and rash leading to permanent discontinuation of alpelisib (Pivikto®) (3.5% vs 4.2%). Accordingly, antihistamines

may be initiated prophylactically, at the time of initiation of treatment with alpelisib (Pivikto®). Based on the severity of rash, alpelisib (Pivikto®) may require dose interruption, reduction, or discontinuation as described in Table 3 Dose modification and management for rash (see section DOSAGE REGIMEN AND ADMINISTRATION).

GI toxicity (nausea, diarrhea, vomiting)

In the phase III study, diarrhea, nausea and vomiting were (see Table 7 Adverse drug reactions) reported in 57.7%, 44.7% and 27.1% of the patients, respectively, and led to discontinuation of alpelisib (Pivikto®) and/or fulvestrant in 8 (2.8%), 5 (1.8%) and 3 (1.1%) of the patients, respectively.

Anti-emetics (e.g. ondansetron) and anti-diarrheal medications (e.g. loperamide) were used in 27/149 (18.1%) and 104/164 (63.4%) of patients to manage symptoms.

Osteonecrosis of the jaw (ONJ)

In the phase III clinical study, ONJ was reported in 4.2% patients (12/284) in the alpelisib (Pivikto®) plus fulvestrant arm compared to 1.4% patients (4/287) in the placebo plus fulvestrant arm. All patients experiencing ONJ were also exposed to prior or concomitant bisphosphonates (e.g. zoledronic acid) or RANK-ligand inhibitors (e.g. denosumab). Therefore, in patients receiving alpelisib (Pivikto®) and bisphosphonates or RANK-ligand inhibitors, an increased risk of development of ONJ cannot be excluded.

INTERACTIONS

The elimination of alpelisib is majorly driven by non-hepatic hydrolysis, mediated by multiple enzymes (esterases, amidases, choline esterase) and, to a lesser degree, CYP3A4 mediated metabolism (hydroxylation). The contribution of hepatobiliary export or intestinal secretion via BCRP in human is considered to be low.

Medicinal products that may increase alpelisib plasma concentrations

BCRP inhibitors

Alpelisib is a sensitive substrate for BCRP (breast cancer resistance protein) *in vitro*, predominantly expressed in the liver, intestine, and at blood-brain barrier. Absorption of alpelisib will not be affected by BCRP inhibition due to saturation of the transporter in the intestine. However, due to the involvement of BCRP in the hepatobiliary export and intestinal secretion of alpelisib, caution is advised when co-administering alpelisib (Pivikto®) with a BCRP inhibitor (e.g. eltrombopag, lapatininb, pantoprazole), as inhibition of BCRP in the liver and in the intestine after absorption may lead to an increase in systemic exposure of alpelisib (Pivikto®).

Medicinal products that may decrease alpelisib plasma concentrations

CYP3A4 inducers

Administration of 600 mg once daily rifampin, a strong CYP3A4 inducer, for 7 days, before co-administration with a single oral 300 mg alpelisib dose on Day 8, decreased alpelisib Cmax by 38% and AUC by 57% in healthy adults (N = 25). Administration of 600 mg once daily rifampin for 15 days, coadministered with daily 300 mg alpelisib starting from Day 8 to Day 15 decreased the steady state alpelisib Cmax by 59% and AUC by 74%.

Co-administration with a strong CYP3A4 inducer decreases alpelisib area under the curve (AUC) (see section CLINICAL PHARMACOLOGY), which may reduce alpelisib efficacy. Co-administration of alpelisib with strong CYP3A4 inducers (e.g., apalutamide, carbamazepine, enzalutamide, mitotane, phenytoin, rifampin, St. John's wort) should be avoided and selection of an alternative concomitant medicinal product, with no or minimal potential to induce CYP3A4, should be considered (see section CLINICAL PHARMACOLOGY).

Medicinal products whose plasma concentrations may be altered by alpelisib

CYP3A4 substrates

No dose adjustment is required when co-administering alpelisib (Pivikto®) with CYP3A4 substrates (e.g. everolimus, midazolam).

Caution is recommended when alpelisib (Pivikto®) is used in combination with CYP3A4 substrates that also possess an additional time-dependent inhibition and induction potential on CYP3A4 that affects their own metabolism (e.g. rifampicin, ribociclib, encorafenib). Systemic exposures of such CYP3A4 auto-inhibitors and auto-inducers may be decreased and increased, respectively, when alpelisib (Pivikto®) is co-administered, based on PBPK (physiologically based pharmacokinetic) simulations.

CYP2C9 substrates with narrow therapeutic index

In vitro evaluations indicate that the pharmacological activity may be reduced by the CYP2C9 induction effects of alpelisib. Based on PBPK modeling data with sensitive CYP2C9 substrate warfarin, after co-administration of alpelisib (300 mg once daily for 20 days), AUC (area under curve) and Cmax (maximum concentration) ratios of warfarin were estimated to be 0.91 and 0.99, respectively, indicating no or weak induction potential of alpelisib on CYP2C9. No dose adjustment is required when alpelisib (Pivikto®) is co-administered with CYP2C9 substrates with narrow therapeutic index (e.g. warfarin). However, in the absence of clinical data, caution is recommended.

CYP2B6 sensitive substrates with narrow therapeutic index

Static mechanistic assessment with sensitive CYP2B6 substrates such as bupropion, a reduction of exposure by up to 3-fold can be expected when co-administered with alpelisib based on *in vitro* assessment, no clinical study was performed. Sensitive CYP2B6 substrates (e.g. bupropion) or CYP2B6 substrates with a narrow therapeutic window should be used with caution in combination with alpelisib (Pivikto®), as alpelisib (Pivikto®) may reduce the clinical activity of such drugs.

Drug-food interactions

In healthy subjects, co-administration of alpelisib with food resulted in an increased AUC of alpelisib by 77% (see section DOSAGE REGIMEN AND ADMINISTRATION and section CLINICAL PHARMACOLOGY). Therefore, alpelisib (Pivikto®) should be taken immediately after food, at approximately same time each day (see section DOSAGE REGIMEN AND ADMINISTRATION).

Hormonal contraceptives

It is currently unknown whether alpelisib may reduce the effectiveness of systemically acting hormonal contraceptives.

PREGNANCY, LACTATION, FEMALES AND MALES OF REPRODUCTIVE POTENTIAL

Pregnancy

Risk summary

Based on animal data and its mechanism of action, alpelisib (Pivikto®) can cause fetal harm when administered to a pregnant woman.

There are no adequate and well-controlled studies in pregnant women. Embryo-fetal development studies in rats and rabbits have demonstrated that oral administration of alpelisib during organogenesis induced embryo-toxicity, feto-toxicity, and teratogenicity. In rats and rabbits, following prenatal exposure to alpelisib, increased incidences of post-implantation loss, reduced fetal weights, and increased incidences of fetal abnormalities were observed starting at doses below (see animal data) the exposure in humans at the highest recommended dose of 300 mg.

Alpelisib should not be used during pregnancy unless the benefits to the mother outweigh the risk to the fetus. If alpelisib (Pivikto®) is used during pregnancy, the patient should be advised of the potential risk to the fetus.

Data

Animal Data

In embryo-fetal development studies in rats and rabbits, pregnant animals received oral doses of alpelisib up to 30 mg/kg/day, during the period of organogenesis.

In rats, oral administration of alpelisib was associated with maternal body weight loss or stagnation, low food consumption and embryonal death at 30 mg/kg/day, approximately 3.2 times (based on AUC) the exposure in humans at the highest recommended dose of 300 mg. Low maternal body weight gain, increased incidences of enlarged brain ventricle in the fetuses, reduced fetal weight, decreased bone ossification and skeletal malformations were seen at 10 mg/kg/day, that is equal to approximately 0.9 times below the exposure in humans at the highest recommended dose.

In rabbits, at doses of ≥25 mg/kg/day, maternal body weight loss with reduced food intake was observed. At 15mg/kg/day, slight transient body weight loss was observed. At ≥ 15 mg/kg/day increased embryo-fetal deaths and malformations were observed, mostly related to the tail and head, and were associated with increased serum glucose levels in dams. At 25 mg/kg/day, reduced mean fetal weight was observed. The dose of 15 mg/kg/day dose in rabbits is equivalent to approximately 5.5 times (based on AUC) the exposure achieved at the highest recommended human dose.

In rats and rabbits, no fetal effects were observed at 3 mg/kg/day, and considered to be the no-observable-adverse-effect-level (NOAEL) for fetal abnormalities. The maternal systemic

exposures (AUC) at the NOAEL were 0.12 (rats) or 0.86 (rabbits) times the exposure in humans at the highest recommended dose of 300 mg.

Lactation

Risk summary

It is not known if alpelisib is transferred into human or animal milk after administration of alpelisib (Pivikto®). There are no data on the effects of alpelisib on the breastfed child or the effects of alpelisib on milk production.

Because of the potential for serious adverse drug reactions in the breastfed child from alpelisib (Pivikto®), it is recommended that women should not breastfeed during treatment and for at least 4 days after the last dose of alpelisib (Pivikto®).

Females and males of reproductive potential

Pregnancy testing

The pregnancy status for females of reproductive potential should be verified prior to starting treatment with alpelisib (Pivikto®).

Contraception

Females of reproductive potential should be advised that animal studies and the mechanism of action have shown that alpelisib can be harmful to the developing fetus. Sexually-active females of reproductive potential should use effective contraception (methods that result in less than 1% pregnancy rates) when using alpelisib (Pivikto®) during treatment and for at least 4 days after stopping treatment with alpelisib. It is currently unknown whether alpelisib may reduce the effectiveness of systemically acting hormonal contraceptives.

Male patients with sexual partners who are pregnant, possibly pregnant, or who could become pregnant should use condoms during sexual intercourse while taking alpelisib (Pivikto®) and for at least 4 days after stopping treatment with alpelisib (Pivikto®).

Infertility

There are no clinical data available on the effect of alpelisib on fertility. Based on repeat dose toxicity studies in animals, alpelisib (Pivikto®) may impair fertility in males and females of reproductive potential (see section NON-CLINICAL SAFETY DATA). In fertility studies conducted in male and female rats, similar effects were observed (see section NON-CLINICAL SAFETY DATA).

OVERDOSAGE

There is limited experience of overdose with alpelisib (Pivikto®) in clinical studies. In the clinical studies, alpelisib (Pivikto®) was administered at doses up to 450 mg once daily.

In cases where accidental overdosage of alpelisib (Pivikto®) was reported in the clinical studies, the adverse events associated with the overdose were consistent with the known safety profile of alpelisib (Pivikto®) and included hyperglycemia, nausea, asthenia and rash.

General symptomatic and supportive measures should be initiated in all cases of overdosage where necessary. There is no known antidote for alpelisib (Pivikto®).

CLINICAL PHARMACOLOGY

Mechanism of action (MOA)

Alpelisib is an α specific class I phosphatidylinositol3kinase (PI3Kalpha) inhibitor.

Class I PI3K lipid kinases are key components of the PI3K/AKT/mTOR (mammalian target of rapamycin) signaling pathway.

Gain-of-function mutations in the gene encoding the catalytic alpha-subunit of PI3K (PIK3CA) lead to activation of PI3Kalpha manifested by increased lipid kinase activity, growth-factor independent activation of Akt-signaling, cellular transformation and the generation of tumors in a diverse array of preclinical models.

In vitro, alpelisib treatment potently inhibited the phosphorylation of PI3K downstream targets Akt as well as its various downstream effectors in breast cancer cells and showed selectivity towards cell lines harboring a PIK3CA mutation.

In vivo, alpelisib showed good tolerability as well as dose-and time-dependent inhibition of the PI3K/Akt pathway and dose-dependent tumor growth inhibition in relevant tumor xenograft models, including models of breast cancer.

PI3K inhibition by alpelisib treatment has been shown to induce an increase in ER transcription in breast cancer cells, therefore, sensitizing these cells to estrogen receptor (ER) inhibition by fulvestrant treatment. Combination of alpelisib and fulvestrant demonstrated increased anti-tumor activity than either treatment alone in xenograft models derived from ER+, PIK3CA mutated breast cancer cell lines (MCF-7 and KPL1).

Pharmacodynamics (PD)

In biochemical assays, alpelisib inhibited wild type PIK3alpha (IC_{50}=4.6 nmol/L) and its 2 most common somatic mutations (H1047R, E545K) (IC_{50}~4 nmol/L) more potently than the PI3Kdelta (IC_{50}=290 nmol/L) and PI3Kgamma (IC_{50}=250 nmol/L) isoforms and showed significantly reduced activity against PI3Kbeta (IC_{50}=1,156 nmol/L).

The potency and selectivity of alpelisib was confirmed at the cellular level in mechanistic and relevant tumor cell lines.

Cardiac electrophysiology

Serial, triplicate ECGs (electrocardiogram) were collected following a single dose and at steady-state to evaluate the effect of alpelisib on the QTcF interval in patients with advanced cancer. A pharmacokinetic-pharmacodynamic analysis included a total of 134 patients treated with alpelisib at doses ranging from 30 to 450 mg.
The analysis demonstrates the absence of a clinically significant QTcF prolongation at the recommended 300 mg dose with or without fulvestrant. The estimated mean change from baseline in QTcF was <10 msecs (7.2 ms; 90% CI: 5.62, 8.83) at the observed geometric-mean Cmax at steady-state (2,900 ng/mL) following single agent administration at the recommended 300 mg dose.

Pharmacokinetics (PK)

The pharmacokinetics of alpelisib were investigated in patients under an oral dosing regimen ranging from 30 to 450 mg daily. Healthy subjects received single oral doses ranging from 300 mg to 400 mg. The PK was mostly comparable in both oncology patients and healthy subjects.

Absorption

Following oral administration of alpelisib, median time to reach peak plasma concentration (Tmax) ranged between 2.0 to 4.0 hours, independent of dose, time or regimen. Based on absorption modelling bioavailability was estimated to be very high (>99%) under fed conditions but lower under fasted conditions (~68.7% at a 300 mg dose). Steady-state plasma levels of alpelisib after daily dosing can be expected to be reached on day 3, following onset of therapy in most patients.

Food effect

Alpelisib absorption is affected by food. In healthy volunteers after a single 300 mg oral dose of alpelisib, compared to the fasted state, a high-fat high-calorie (HFHC) meal (985 calories with 58.1 g of fat) increased AUCinf by 73% and Cmax by 84%, and a low-fat low-calorie (LFLC) meal (334 calories with 8.7 g of fat) increased AUCinf by 77% and Cmax by 145%. No significant difference was found for AUCinf between LFLC and HFHC with a geometric mean ratio of 0.978 [CI: 0.876, 1.09] showing that neither fat content nor overall caloric intake has a considerable impact on absorption. The increase in gastrointestinal solubility by bile, secreted in response to food intake, is considered to be the driver of the food effect. Hence, alpelisib (Pivikto®) should be taken immediately after food, at approximately the same time each day.

Acid reducing agents

The co-administration of the H2 receptor antagonist ranitidine in combination with a single 300 mg oral dose of alpelisib slightly reduced the bioavailability of alpelisib and decreased overall exposure of alpelisib. In the presence of a LFLC meal, AUCinf was decreased on average by 21% and Cmax by 36% with ranitidine. In the absence of food, the effect was more pronounced with a 30% decrease in AUCinf and a 51% decrease in Cmax with ranitidine compared to the fasted state without co-administration of ranitidine. alpelisib (Pivikto®) can be co-administered with drugs that are acid-reducing agents, if alpelisib (Pivikto®) is taken immediately after food. Population pharmacokinetic analysis showed no significant effect on the PK of alpelisib (Pivikto®) by co-administration of acid reducing agents including proton pump inhibitors, H2 receptor antagonists and antacids.

Distribution

Alpelisib moderately binds to protein with a free fraction of 10.8% regardless of concentration. Alpelisib was equally distributed between red blood cells and plasma with a mean *in vivo* blood-to-plasma ratio of 1.03. There was no evidence for distribution into red blood cells caused by metabolites. Alpelisib did not penetrate the blood-brain-barrier in rats. As alpelisib (Pivikto®) is a substrate of human efflux transporters, penetration of the blood-brain-barrier is not expected to occur in human. The volume of distribution of alpelisib at steady-state (Vss/F) is estimated at 114 L (intersubject CV% 46%).

Biotransformation/metabolism

In vitro studies demonstrated that formation of the hydrolysis metabolite BZG791 by chemical and enzymatic amide hydrolysis was a major metabolic pathway, followed by CYP3A4 mediated hydroxylation. Alpelisib hydrolysis occurs systemically by both chemical decomposition and enzymatic hydrolysis via ubiquitously expressed, high-capacity enzymes (esterases, amidases, choline esterase) not limited to the liver. CYP3A4-mediated metabolites and glucuronides amounted to ~15% of the dose BZG791 accounted for ~40 to 45% of the dose. The rest of the dose, which was found as unchanged alpelisib in urine and feces, was either excreted as alpelisib or non-absorbed.

Elimination

Alpelisib exhibits low clearance with 9.2 L/hr (CV% 21%) based on population PK analysis under fed conditions. The population derived half-life, independent of dose and time, was 8 to 9 hours at steady state of 300 mg, once daily.

In human mass-balance study, after oral administration, alpelisib and its metabolites were primarily found in the feces (81.0%), as alpelisib or metabolized as BZG791. Excretion in the urine is minor (13.5%), with 2% of unchanged alpelisib. Following single oral dose of [14C]-alpelisib, 94.5% of the total administered radioactive dose was recovered within 8 days.

Linearity/non-linearity

The pharmacokinetics were found to be linear with respect to dose and time under fed conditions between 30 and 450 mg. After multiple doses, alpelisib exposure (AUC) at steady-state is only slightly higher than that of a single dose with an average accumulation of 1.3 to 1.5 with a daily dosing regimen.

Metabolic interaction

Based on the results of metabolic *in vitro* induction and inhibition studies, alpelisib may induce the metabolic clearance of co-medications metabolized by CYP2B6, CYP2C9 and CYP3A4 and may inhibit the metabolic clearance of co-medications metabolized CYP3A4 (time-dependent inhibition) if sufficiently high concentrations are achieved *in vivo*.

In a drug-drug interaction study, co-administration of alpelisib with everolimus, a sensitive CYP3A4 substrate, confirmed that there are no clinically significant pharmacokinetic interactions (increase in AUC by 11.2%) between alpelisib and CYP3A4 substrates. No change in everolimus exposure was observed at alpelisib doses ranging from 250 to 300 mg, also confirmed by PBPK modeling with everolimus and midazolam ($\leq$ 15% increase in AUC). Due to the concurrent induction and time-dependent inhibition by alpelisib, PBPK simulations with substrates of CYP3A4 that also possess an additional time-dependent inhibition and induction potential on CYP3A4 that affects their own metabolism predict changes in exposure (decrease or increase) less than 2-fold, depending on the substrate.

In a drug-drug interaction study, co-administration of alpelisib with rifampin, a strong CYP3A4 inducer, confirmed that there is a clinically significant pharmacokinetic interaction between alpelisib and strong CYP3A4 inducers leading to a decrease in AUC by 57% and 74% for a single 300 mg dose and a repeated 300 mg dose of alpelisib, respectively (see section INTERACTIONS).

CYP2C9 substrates

In lieu of a clinical study, PBPK modeling showed that AUC and Cmax ratios of warfarin (10 mg single dose) were estimated to be 0.91 and 0.99, respectively, after repeated co-administration of alpelisib (300 mg), indicating no or weak induction potential of alpelisib on CYP2C9.

Transporter-based interaction

Alpelisib showed only weak *in vitro* inhibition towards the ubiquitously expressed efflux transporters (P-gp, BCRP, MRP2, BSEP), solute carrier transporters at the liver inlet (OATP1B1, OATP1B3, OCT1) and solute carrier transporters in the kidney (OAT1, OAT3, OCT2, MATE1, MATE2K. As unbound systemic steady state concentrations (or concentrations at the liver inlet) at both the therapeutic dose and maximum tolerated dose are significantly lower than the experimentally determined unbound inhibition constants or IC50, the inhibition will not translate into clinical significance. A clinically relevant effect on P-gp substrates can be excluded.

Fulvestrant: Data from a clinical study in patients with breast cancer indicated no effect of fulvestrant on alpelisib exposure (and vice versa) following co-administration of the drugs.

Special populations

Effect of age, weight and gender

The population PK analysis showed that there are no clinically relevant effects of age, body weight, or gender on the systemic exposure of alpelisib that would require alpelisib (Pivikto®) dose adjustment.

Pediatric patients (below 18 years)

The pharmacokinetics of alpelisib (Pivikto®) in pediatric patients have not been established.

Geriatric patients (65 years or above)

Of 284 patients who received alpelisib (Pivikto®) in the phase III study (in alpelisib (Pivikto®) plus fulvestrant arm), 117 patients were ≥65 years of age and 34 patients were ≥75 years of age. No overall differences in safety or effectiveness of alpelisib (Pivikto®) were observed between these patients and younger patients (see section DOSAGE REGIMEN AND ADMINISTRATION).

Race/Ethnicity

Population PK analyses and PK analysis from a single agent study in Japanese cancer patients showed that there are no clinically relevant effects of ethnicity on the systemic exposure of alpelisib (Pivikto®).

Non-compartmental PK parameters after single and multiple daily doses of alpelisib (Pivikto®) for Japanese patients were very similar to those reported in the Caucasian population.

Renal impairment

No dose adjustment is necessary in patients with mild or moderate renal impairment. Patients with severe renal impairment have not been studied and caution should be used. Based on a population pharmacokinetic analysis that included 117 patients with normal renal function

(eGFR [estimated glomerular filtration rate] $\geq$90 mL/min/1.73 m²) / (CLcr $\geq$90 mL/min), 108 patients with mild renal impairment (eGFR 60 to <90 mL/min/1.73m²)/ (CLcr 60 to <90 mL/min), and 45 patients with moderate renal impairment (eGFR 30 to <60 mL/min/1.73 m²), mild and moderate renal impairment had no effect on the exposure of alpelisib (see section DOSAGE REGIMEN AND ADMINISTRATION).

Hepatic impairment

No dose adjustment is necessary in patients with mild, moderate or severe hepatic impairment (Child-Pugh A, B and C).

Based on a pharmacokinetic trial in patients with hepatic impairment, moderate and severe hepatic impairment had negligible effect on the exposure of alpelisib (see section DOSAGE REGIMEN AND ADMINISTRATION). The mean exposure for alpelisib was increased by 1.26-fold in patients with severe (GMR [geometric mean ratio]: 1.00 for C_{max}; 1.26 for AUC_{last} /AUC_{inf}) hepatic impairment.

Based on a population pharmacokinetic analysis that included 230 patients with normal hepatic function, 45 patients with mild hepatic impairment and no patients with moderate hepatic impairment, further supporting the findings from the dedicated hepatic impairment study, mild and moderate hepatic impairment had no effect on the exposure of alpelisib, (see section DOSAGE REGIMEN AND ADMINISTRATION).

CLINICAL STUDIES

Alpelisib (Pivikto®) was evaluated in a pivotal phase III, randomized, double-blind, placebo controlled study of alpelisib (Pivikto®) in combination with fulvestrant in men and postmenopausal women with HR+, HER2- locally advanced breast cancer whose disease had progressed or recurred on or after an aromatase inhibitor based treatment (with or without CDK4/6 combination).

A total of 572 patients were enrolled into two cohorts, cohort with PIK3CA mutation or cohort without PIK3CA mutation breast cancer. PIK3CA mutation status was determined by clinical trial assays. Patients were randomized to receive either alpelisib (Pivikto®) 300 mg plus fulvestrant or placebo plus fulvestrant in a 1:1 ratio. Randomization was stratified by presence of lung and/or liver metastasis and previous treatment with CDK4/6 inhibitor(s).

Within the cohort with a PIK3CA mutation, 169 patients were randomized to receive alpelisib (Pivikto®) in combination with fulvestrant and 172 patients were randomized to placebo in combination with fulvestrant. Within this cohort, 170 (49.9%) patients had liver/lung metastases and 20 (5.9%) patients had received prior CDK4/6 inhibitor treatment.

Within the cohort without PIK3CA mutation, 115 patients were randomized to receive alpelisib (Pivikto®) in combination with fulvestrant and 116 were randomized to receive placebo in combination with fulvestrant. 112 (48.5%) patients had liver/lung metastases and 15 (6.5%) patients had prior CDK4/6 inhibitor treatment.

In the cohort with PIK3CA mutation, 97.7% of patients received prior hormonal therapy and 47.8% of patients had the last setting as metastatic and 51.9% of patients whose last setting was adjuvant therapy. Overall, 85.6% of the patients were considered to have endocrine resistant disease; primary endocrine resistance was observed in 13.2% and secondary endocrine resistance in 72.4% of patients.

In both cohorts with or without PIK3CA mutation, demographics and baseline disease characteristics, ECOG (Eastern Cooperative Oncology Group) performance status, tumor burden, and prior antineoplastic therapy were well balanced between the study arms.

During the randomized treatment phase, alpelisib (Pivikto®) 300 mg or alpelisib (Pivikto®) matching placebo was administered orally once daily on a continuous basis. Fulvestrant 500 mg was administered intramuscularly on Cycle 1 Day 1 and 15 and then at Day 1 of a 28-day cycle during treatment phase (administration +/- 3 days).

Patients were not allowed to cross over from placebo to alpelisib (Pivikto®) during the study or after disease progression.

The primary endpoint for the study was progression-free survival (PFS) using Response Evaluation Criteria in Solid Tumors (RECIST v1.1), based on the investigator assessment in patients with a PIK3CA mutation. The key secondary endpoint was overall survival (OS) for patients with a PIK3CA mutation.

Other secondary endpoints included PFS for patients without a PIK3CA mutation, OS for patients without a PIK3CA mutation, as well as overall response rate (ORR) and clinical benefit rate (CBR) by PIK3CA mutation cohort.

Cohort with PIK3CA mutation

Patients enrolled with a PIK3CA mutation had a median age of 63 years (range 25 to 92). 44.9% patients were 65 years of age or older and <85 years. The patients included were White (66.3%), Asian (21.7%), Black or African American (1.2%).

Primary analysis

The study met its primary objective at the final PFS analysis (data cut-off date 12-June-2018) demonstrating statistically significant improvement in PFS by investigator assessment in the PIK3CA mutant cohort for patients receiving alpelisib (Pivikto®) plus fulvestrant, compared to patients receiving placebo plus fulvestrant (HR = 0.65 with 95% CI: 0.50, 0.85; one sided stratified log-rank test p= 0.00065), with an estimated 35% risk reduction of disease progression or death in favor of treatment with alpelisib (Pivikto®) plus fulvestrant. The median PFS was prolonged by 5.3 months, from 5.7 months (95% CI: 3.7, 7.4) in the placebo plus fulvestrant arm to 11 months (95% CI: 7.5, 14.5) in the alpelisib (Pivikto®) plus fulvestrant arm.

Primary PFS results were supported by consistent results from a blinded independent review committee (BIRC) assessment in this cohort, which included a randomly selected subset of 50% of randomized patients (HR= 0.48 with 95% CI: 0.32, 0.71).

PFS results are summarized in Table 10, Figure 1 and 2.

Table 10   **Study C2301- Primary efficacy analysis – Summary of results based on RECIST (FAS,cohort with PIK3CA mutation)**

	Alpelisib (Pivikto®) + Fulvestrant (n=169)	Placebo + Fulvestrant (n=172)	Hazard ratio (HR)	p-value[a]
Median progression free survival (PFS[a]) (months, 95% CI)				
Investigator radiological assessment				
PIK3CA mutant cohort (N=341)	11.0 (7.5 to 14.5)	5.7 (3.7 to 7.4)	0.65 (0.50 to 0.85)	0.00065

	Alpelisib (Pivikto®) + Fulvestrant (n=169)	Placebo + Fulvestrant (n=172)	Hazard ratio (HR)	p-value[a]
Blinded independent review committee assessment*				
PIK3CA mutant cohort (N=173)	11.1 7.3 to 16.8	3.7 2.1 to 5.6	0.48 (0.32 to 0.71)	N/A

Data cut-off date: 12JUN2018
CI=confidence interval; N=number of patients; N/A = is not applicable
[a]p-value is obtained from the one-sided stratified log-rank test.
*Sample-based audit approach of 50% randomized patients

Figure 1　　**Study C2301 primary efficacy analysis - Kaplan-Meier plot of PFS per investigator assessment (FAS, PIK3CA mutant cohort). Data cut-off date: 12-Jun-2018.**

Figure 2   **Study C2301 Kaplan-Meier plot of PFS per BIRC assessment (FAS, PIK3CA mutant cohort). Data cut-off date: 12-Jun-2018.**

PFS subgroup analyses by randomization stratification factors demonstrated a homogeneous and generally consistent treatment effect per investigator assessment across major demographic and prognostic subgroups irrespective of CDK4/6i prior treatment and presence or absence of lung/liver metastases.

Although limited in patient numbers, for the analysis of prior CDK4/6i treatment sub-group, the HR (95% CI) for PFS was 0.48 (0.17, 1.36).

In the subgroup of patients with presence of lung/liver metastases, the HR (95% CI) was 0.62 (0.44, 0.89). See Figure 3.

Figure 3   Study C2301 - PFS per investigator assessment in major demographic and prognostic subgroups (FAS, PIK3CA mutant cohort). Data cut-off date: 12-Jun-2018.

(panel A)

	Hazard ratio (95% CI)	Alpelisib 300mg qd + Fulv n/N(%)	Placebo qd + Fulv n/N(%)
All subjects	0.65(0.50,0.85)	103/169(60.9)	129/172(75.0)
Lung and/or Liver metastases			
Present	0.62(0.44,0.89)	53/84(63.1)	72/86(83.7)
Absent	0.69(0.47,1.01)	50/85(58.8)	57/86(66.3)
Presence of lung metastases			
No	0.62(0.44,0.87)	68/112(60.7)	76/104(73.1)
Yes	0.65(0.42,1.01)	35/57(61.4)	53/68(77.9)
Presence of liver metastases			
No	0.70(0.50,0.97)	67/120(55.8)	79/118(66.9)
Yes	0.58(0.37,0.90)	36/49(73.5)	50/54(92.6)
Bone lesions only			
No	0.66(0.49,0.88)	85/127(66.9)	108/137(78.8)
Yes	0.62(0.33,1.18)	18/42(42.9)	21/35(60.0)
Prior CDK4/6 inhibitor			
Prior use	0.48(0.17,1.36)	7/9(77.8)	10/11(90.9)
No prior use	0.67(0.51,0.87)	96/160(60.0)	119/161(73.9)

0.0625   0.25 0.5   1   2   4

<---------------- -------->

Alpelisib better   Placebo better
Hazard ratio (Alpelisib/Placebo) and 95% CI

(panel B)

	Hazard ratio (95% CI)	Alpelisib 300mg qd + Fulv n/N(%)	Placebo qd + Fulv n/N(%)
PTEN loss of expression			
No	0.69(0.53,0.90)	99/163(60.7)	115/157(73.2)
Yes	0.19(0.04,0.88)	4/6(66.7)	14/14(100.0)
Age (years)			
< 65 Years	0.62(0.43,0.89)	58/95(61.1)	64/89(71.9)
>= 65 Years	0.70(0.47,1.03)	45/74(60.8)	65/83(78.3)
Age (years)			
< 75 Years	0.61(0.46,0.80)	89/149(59.7)	111/146(76.0)
>= 75 Years	1.12(0.54,2.34)	14/20(70.0)	18/26(69.2)
Race			
Asian	0.76(0.43,1.35)	21/34(61.8)	31/40(77.5)
White	0.56(0.41,0.78)	69/117(59.0)	80/109(73.4)
Other	0.91(0.41,2.00)	12/17(70.6)	17/20(85.0)
Region			
Europe	0.56(0.39,0.81)	50/86(58.1)	67/87(77.0)
North America	0.41(0.19,0.91)	11/19(57.9)	21/24(87.5)
Asia	0.76(0.42,1.37)	20/32(62.5)	29/38(76.3)
Latin America	1.43(0.54,3.79)	9/14(64.3)	9/17(52.9)
Other	0.93(0.25,3.45)	13/18(72.2)	3/6(50.0)
ECOG performance status			
0	0.71(0.51,0.99)	67/112(59.8)	79/113(69.9)
1	0.58(0.38,0.91)	36/56(64.3)	49/58(84.5)
Endocrine status			
Primary resistant	0.64(0.31,1.32)	16/23(69.6)	17/22(77.3)
Secondary resistant	0.66(0.49,0.90)	73/120(60.8)	100/127(78.7)
Sensitive	0.87(0.35,2.17)	11/20(55.0)	9/19(47.4)

0.0625   0.5   1   2   4

<------------------ -------->

Alpelisib better   Placebo better
Hazard ratio (Alpelisib/Placebo) and 95% CI

(panel C)

|	Hazard ratio (95% CI)	Alpelisib 300mg qd + Fulv n/N(%)	Placebo qd + Fulv n/N(%)
Line of adv. anti-cancer trt			
First Line	0.71(0.49,1.03)	51/88(58.0)	64/89(71.9)
Second Line	0.61(0.42,0.89)	50/79(63.3)	65/82(79.3)
Prior chemotherapy use			
Adjuvant	0.63(0.42,0.95)	43/77(55.8)	55/84(65.5)
Neoadjuvant	0.37(0.17,0.80)	11/24(45.8)	18/22(81.8)
No Prior Use	0.87(0.58,1.29)	49/68(72.1)	55/65(84.6)
Endocr. Status & Line of Therapy			
1L: endocrine sensitive	0.87(0.35,2.17)	11/20(55.0)	9/19(47.4)
1L: endocrine resistant	0.69(0.46,1.05)	40/68(58.8)	55/70(78.6)
2L: PD post(neo)adj/metastatic Tx	0.46(0.20,1.05)	12/23(52.2)	17/23(73.9)
2L: PD post metastatic Tx only	0.67(0.40,1.11)	30/42(71.4)	38/45(84.4)
Prior Tamoxifen use			
No	0.71(0.51,0.98)	69/110(62.7)	87/110(79.1)
Yes	0.55(0.35,0.88)	34/59(57.6)	42/62(67.7)
Estrogen receptor status			
Positive	0.67(0.51,0.86)	102/167(61.1)	129/172(75.0)
Progesterone receptor status			
Positive	0.67(0.49,0.91)	68/120(56.7)	99/132(75.0)
Negative	0.60(0.35,1.03)	33/46(71.7)	28/38(73.7)
Estr. & Progest. receptor status			
Both positive	0.69(0.50,0.94)	67/118(56.8)	99/132(75.0)
Positive Negative	0.60(0.35,1.03)	33/46(71.7)	28/38(73.7)
Number of metastatic sites			
< 3	0.59(0.43,0.83)	66/121(54.5)	81/113(71.7)
>= 3	0.77(0.50,1.20)	37/48(77.1)	48/59(81.4)
Visceral disease			
No	0.69(0.45,1.06)	41/76(53.9)	45/72(62.5)
Yes	0.65(0.47,0.90)	62/93(66.7)	84/100(84.0)

0.0625   0.25 0.5   1   2   4

<----------------- -------->

Alpelisib better   Placebo better

Hazard ratio (Alpelisib/Placebo) and 95% CI

Treatment with the combination of alpelisib (Pivikto®) plus fulvestrant was associated with marked improvements in ORR and CBR relative to placebo + fulvestrant. See Table 11 for details.

Table 11 **Study C2301-Overall response rate and clinical benefit rate per investigator assessment (FAS, PIK3CA mutant cohort). Data cut-off date: 12 Jun 2018**

Analysis	Alpelisib (Pivikto®) plus fulvestrant (%, 95% CI)	Placebo plus fulvestrant (%, 95% CI)	p-value[c]
Full analysis set	N=169	N=172	
Objective Response Rate[a]	26.6 (20.1 to 34.0)	12.8 (8.2 to 18.7)	0.0006
Clinical Benefit Rate[b]	61.5 (53.8 to 68.9)	45.3 (37.8 to 53.1)	0.002
Patients with measurable disease	**N=126**	**N=136**	
Objective Response Rate[a]	35.7 (27.4 to 44.7)	16.2 (10.4 to 23.5)	0.0002
Clinical Benefit Rate[b]	57.1 (48.0 to 65.9)	44.1 (35.6 to 52.9)	0.02

[a] *ORR= proportion of patients with confirmed Complete Response or Partial Response*
[b] *CBR: proportion of patients with confirmed Complete Response or Partial Response, or (Stable Disease or Non-Complete Response/Non-Progression Disease >=24 weeks)*

[c] *p-value is obtained from the Cochran-Mantel Haenszel test.*

The global health status/Quality of Life (QoL) outcomes were similar between the alpelisib (Pivikto®) plus fulvestrant arm and the placebo plus fulvestrant arm. Time-to-Deterioration (TTD) in global health status EORTC QLQ-C30 (European Organization for Research and Treatment of Cancer Quality-of-life Questionnaire Core 30) was defined as time between baseline and first occurrence of ≥10 point worsening of global health status (EORTC QLQ-C30 global health scale score) compared to baseline with no later improvement above this threshold observed during the treatment period or death due to any cause. The addition of alpelisib (Pivikto®) to fulvestrant showed no relevant difference in TTD in EORTC QLQ-C30 global health scale score compared with placebo plus fulvestrant, (HR=1.03; 95% CI:0.72, 1.48).

Final OS Analysis

The final OS analysis was conducted using a data cut-off date of 23-Apr-2020 and PFS was re-run using this data cut. With a median duration from randomization to data cut-off of approximately 42 months, the PFS benefit was sustained and consistent with results from the final PFS analysis. There was an estimated 36% risk reduction of progression or death in favor of treatment with alpelisib (Pivikto®) plus fulvestrant (HR = 0.64; 95% CI: 0.50, 0.81). See Figure 4 for details.

Figure 4   **Study C2301 - Kaplan-Meier plot of PFS per investigator assessment (FAS, PIK3CA mutant cohort): descriptive update with data cut-off date of 23-Apr-2020.**


At the final OS analysis, the study did not meet its key secondary objective. As of the data cut-off date of 23-Apr-2020, a total of 87 (51.5%) deaths were reported in the alpelisib (Pivikto[®]) plus fulvestrant arm and 94 (54.7%) in the placebo plus fulvestrant arm. The HR was 0.86 (95% CI: 0.64, 1.15; p = 0.15, one-sided) and the pre-specified O'Brien-Fleming efficacy boundary of p ≤ 0.0161 was not crossed. Median OS was prolonged by a clinically relevant 7.9 months, from 31.4 months (95% CI: 26.8, 41.3) in the placebo plus fulvestrant arm to 39.3 months (95% CI: 34.1, 44.9) in the alpelisib (Pivikto[®]) plus fulvestrant arm. See Figure 5 for details.

Figure 5   **Study C2301 key secondary analysis - Kaplan-Meier plot of OS (FAS, PIK3CA mutant cohort) with cut-off date of 23-Apr-2020.**

OS subgroup analyses by randomization stratification factors demonstrated a homogeneous and generally consistent treatment effect per investigator assessment. Although limited in patient numbers, for the analysis of prior CDK4/6i treatment subgroup, median OS in the alpelisib (Pivikto®) plus fulvestrant arm was 29.8 months (95% CI: 6.7, 38.2) compared to 12.9 months (95% CI: 2.5, 34.6) in the placebo plus fulvestrant arm. In the subgroup of patients with presence of lung/liver metastases, median OS in the alpelisib (Pivikto®) plus fulvestrant arm was 37.2 months (95% CI: 28.7, 43.6) compared to 22.8 months (95% CI: 19, 26.8) in the placebo plus fulvestrant arm.

Cohort without PIK3CA mutation

The proof of concept criteria to conclude a treatment benefit with alpelisib (Pivikto®) and fulvestrant with respect to PFS in patients in the PIK3CA non-mutant cohort were not met (HR = 0.85; 95% CI: 0.58, 1.25) (see section DOSAGE REGIMEN AND ADMINISTRATION).

NON-CLINICAL SAFETY DATA

Alpelisib was evaluated in safety pharmacology, single- and repeated dose toxicity, genotoxicity and photo-toxicity studies.

Safety pharmacology and repeat dose toxicity

The majority of the observed alpelisib effects were related to the pharmacological activity of alpelisib as a p110alpha specific inhibitor of the PI3K pathway, such as the influence on the glucose homeostasis resulting in hyperglycemia and the risk of increased blood pressure.

The bone marrow and lymphoid tissue, pancreas, and some reproductive organs of both genders were the main target organs for adverse effects, which were generally reversible upon cessation of treatment. Alpelisib showed no effect on neuronal or pulmonary function. No evidence of skin irritation or corrosion was observed with alpelisib.

Cardiovascular safety pharmacology: In an *in vitro* hERG (human Ether-à-go-go-Related Gene) test, (where functionality of the human cardiac hERG channel heterologously expressed in HEK293 cells *in vitro* is assessed), an IC_{50} of 9.4 microM (4.2 microgram/mL) was found. No relevant electrophysiological effect was seen in dogs in several studies, up to single doses of 180 mg/kg *in-vivo*. An *in vivo* telemetry study in dogs showed an elevated blood pressure, starting at exposure lower than the exposure in humans, at the highest recommended dose of 300 mg/day.

Carcinogenicity and mutagenicity

No carcinogenicity studies have been conducted.

Alpelisib was not mutagenic in a *Salmonella* reverse mutation test in five strains, or aneugenic or clastogenic in human cell micronucleus and chromosome aberration tests *in vitro*. Also, an *in vivo* micronucleus test in peripheral blood reticulocytes obtained in week 4 of a 13-week rat repeated-dose toxicity study at dose levels of up to 20 mg/kg/day, at plasma exposure levels of about 1.7 times the exposure in humans at the highest recommended dose of 300 mg/day based on AUC, was negative.

Fertility and Reproductive toxicity

Please see section PREGNANCY, LACTATION, FEMALES AND MALES OF REPRODUCTIVE POTENTIAL.

In repeated-dose toxicity studies up to 13 weeks duration, adverse effects were observed in reproductive organs of females and males, such as vaginal atrophy and oestrus cycle variations in rats (at or above 6 mg/kg/day, a dose that provides plasma exposure levels below the exposure in humans, at the highest recommended dose of 300 mg/day based on AUC), or prostate atrophy in dogs (at 15 mg/kg/day, at plasma exposure levels about 2.8 times the exposure in humans, at the highest recommended dose of 300 mg/day based on AUC) (see section PREGNANCY, LACTATION, FEMALES AND MALES OF REPRODUCTIVE POTENTIAL). In general, the observed effects were reversible upon treatment discontinuation.

In fertility studies conducted in male and female rats, similar effects on fertility were observed. In females at doses of 20 mg/kg/day (approximately 1.7 times the estimated exposure (AUC) in humans at the recommended dose of 300 mg), increased pre- and post-implantation losses led to reduced numbers of implantation sites and live embryos. The NOAEL (No-observed-adverse-effect-level) for female fertility was determined at 10 mg/kg/day (at exposure levels (AUC) at or below the recommended human dose of 300 mg). In males, at doses of ≥ 10 mg/kg/day, accessory glands weights (seminal vesicles, prostate) were reduced and correlated microscopically with atrophy and/or reduced secretion in prostate and seminal vesicles, respectively. Male fertility parameters were unaffected at doses up to 20 mg/kg/day.

Toxicokinetic endpoints were not included in either of the two fertility studies since the toxicokinetic parameters of alpelisib in rats had been sufficiently established earlier.

Phototoxicity

An *in vitro* phototoxicity test on the on the mouse Balb/c 3T3 fibroblast cell line did not identify a relevant phototoxicity potential for alpelisib.

Juvenile animal studies

Juvenile animal studies are not available.

INCOMPATIBILITIES

Not applicable.

AVAILABILITY

- **200 mg Film-Coated Tablet:** Alu/PVC/PCTFE Blister Pack (2x7's) enclosed in a carton wallet
    - Box of 14's *(14-day supply)*
- **1 x 200 mg + 1 x 50 mg Film-Coated Tablets (250mg daily dose):** Alu/PVC/PCTFE Blister Pack (2x7's) enclosed in a carton wallet
    - *Box of 28's (14-day supply):* 14 tabs x 200 mg alpelisib + 14 tabs x 50 mg alpelisib
- **2 x 150 mg Film-Coated Tablets (300 mg daily dose):** Alu/PVC/PCTFE Blister Pack (2x7's) enclosed in a carton wallet
    - *Box of 28's (14-day supply)*

STORAGE

Store at temperatures not exceeding 30°C. Protect from moisture.

The drug should not be used after the date marked "EXP" on the pack.

Drugs must be kept out of the reach and sight of children.

> **CAUTION:** Foods, Drugs, Devices, and Cosmetics Act prohibits dispensing without prescription.

For suspected adverse drug reaction, report to the FDA: **www.fda.gov.ph**

The patient is advised to seek IMMEDIATE medical attention at the first sign of adverse drug reaction.

Manufactured by:
Novartis Pharma Stein AG
Schaffhauserstrasse, 4332 Stein, Switzerland

Packaged by:
Lek Pharmaceuticals d.d.,
Verovškova ulica 57, Ljubljana, 1526, Slovenia

Imported by:
Novartis Healthcare Philippines, Inc.
5th and 6th Floors Ayala North Exchange Building, Tower 1,

Ayala Avenue corner Salcedo & Amorsolo Sts.,
Brgy. San Lorenzo, Makati, Metro Manila

FDA Registration No. / First Registration Date:
- **200 mg Film-Coated Tablet (200mg daily dose):** DR-XY47676/ 20 Jan 2022
- **1 x 200 mg + 1 x 50 mg Film-Coated Tablets (250mg daily dose):** DR-XY47677/ 20 Jan 2022
- **2 x 150 mg Film-Coated Tablets (300 mg daily dose):** DR-XY47678/ 20 Jan 2022

Information issued: December 2021

® = registered trademark

Novartis Pharma AG, Basel, Switzerland